The General Assembly of Qatar Cancer Society (QCS) has endorsed Dr Khalid bin Jabr al-Thani as chairman of QCS at its Ordinary General Assembly Meeting held recently. The Ordinary General Assembly Meeting, chaired by Dr Khalid bin Jabr al-Thani, reviewed the institutional and programmatic achievements of QCS in 2025.
It highlighted QCS’ tangible impact in supporting patients, raising community awareness, advancing professional development, and promoting scientific research. The meeting also underscored efforts to strengthen national and international partnerships, reinforcing the position of QCS as a key national pillar in Qatar’s cancer control ecosystem.
In accordance with QCS’ bylaws, the chair announced that the candidates for board membership for the 2026–2029 term were elected by acclamation. The general assembly approved the election of the following: Dr Khalid bin Jabr al-Thani (chairman), Dr Abdulazim Abdulwahab Hussein (vice-chairman), and board members Dr Khalid Abdullah al-Ali, Mohammed Juma al-Kuwari and Mohammed Issa al-Fadala.
QCS affirmed that 2025 marked a significant milestone in its journey, as it continued to translate its vision into tangible achievements through a comprehensive package of initiatives and services targeting patients, survivors, and the wider community.
Founded in 1997 as a charitable organisation operating under the supervision of the Regulatory Authority for Charitable Activities, QCS is a key national pillar in Qatar’s cancer control system. QCS is guided by a clear vision of "a cancer-aware community and a better life for those affected,” and a humanitarian mission that relies on donations and community partnerships to provide awareness services, as well as financial, psychological, and social support for patients, survivors, and their families, in addition to contributing to professional development and scientific research in the field of cancer.
In 2025, the society continued its humanitarian role in supporting patients unable to afford treatment through its digital platform ‘Wayyakom’, covering the treatment of approximately 1,750 adult and paediatric patients at an estimated cost of QR49mn. Additionally, 1,200 individuals directly benefited from psychological and social support programmes, while indirect beneficiaries exceeded 40,000, alongside specialised individual psychological support services provided to 50 survivors.
In the field of community awareness—considered the first line of defence against cancer—QCS continued to implement specialised campaigns and programmes through its Cancer Awareness Centre, the first of its kind in the Middle East. In 2025, more than 6.65mn indirect beneficiaries were served, in addition to 18,950 direct beneficiaries through workshops, programmes, and field awareness activities.